Clinical Research Directory
Browse clinical research sites, groups, and studies.
Multi-omics Study of Cervical Neuroendocrine Carcinoma
Sponsor: Peking Union Medical College Hospital
Summary
This is a retrospective study using archived tumor tissue and medical records from patients with cervical neuroendocrine carcinoma treated at Peking Union Medical College Hospital since January 1, 2015. Cervical neuroendocrine carcinoma is a rare and highly aggressive cervical cancer with no standard treatment. The study will analyze the tumor's genes, RNA, proteins, and immune environment to better understand its molecular features, identify molecular subtypes, find markers related to survival and immunotherapy, and build a prognostic prediction model. No new patients will be enrolled, and no additional tests or treatments will be given. About 80-120 patients are expected to be included. Results may help improve future diagnosis and personalized treatment for this rare cancer.
Official title: A Real-World Retrospective Multi-Omics Study of Cervical Neuroendocrine Carcinoma
Key Details
Gender
FEMALE
Age Range
18 Years - 100 Years
Study Type
OBSERVATIONAL
Enrollment
120
Start Date
2026-11-01
Completion Date
2026-12-30
Last Updated
2026-10-16
Healthy Volunteers
No
Conditions
Interventions
Multi-omics profiling of archived tumor tissue (observational)
This is a retrospective, observational multi-omics study. No therapeutic intervention (drug, device, procedure, or behavioral modification) is administered to patients. The "intervention" in this context refers solely to the molecular profiling performed on archived tumor tissue specimens and the retrospective collection of clinical data. The multi-omics profiling includes whole-exome sequencing (WES) or large-panel targeted sequencing, strand-specific RNA sequencing, mass spectrometry-based proteomics, and multiplex immunofluorescence/immunohistochemistry (mIF/IHC). These assays are designed to comprehensively characterize the genomic, transcriptomic, proteomic, and tumor immune microenvironment landscape of cervical neuroendocrine carcinoma (NECC). This distinguishes the present study from others by its integrated multi-omics approach and focus on molecular subtyping, rather than evaluating a specific therapeutic agent.
Locations (1)
Peking Union Medical College Hospital
Beijing, China